iGENETECH has been selected as one of the participating companies in the 2026 North America Market Entry Support Program, organized by Seoul Bio Hub under the Seoul Metropolitan Government. The program identifies Korean life sciences and medical technology companies with validated technology and global potential, and supports their structured entry into the North American market through mentorship, clinical network access, and U.S. ecosystem engagement.
What this program represents
North America remains the world's most demanding — and most consequential — market for in vitro diagnostics. Regulatory standards are high, clinical expectations are rigorous, and the bar for partnership is set accordingly. Being selected for this program is not simply an endorsement; it is the beginning of a structured process of market validation: engaging with U.S. healthcare experts, clinical stakeholders, and industry partners to test assumptions, refine our commercialization strategy, and build the relationships that matter.
For iGENETECH, this is a natural next step. The MoiM Dx Platform — a 16-plex molecular diagnostics system with results in under 60 minutes — was built for settings where diagnostic access is limited and speed is critical. That vision is as relevant in decentralized U.S. clinical environments as it is in resource-limited settings globally. The U.S. market does not simply represent scale. It represents validation at the highest standard.
What comes next
iGENETECH will be present at ADLM 2026 in Anaheim, California (July 26–30), our first major North America-facing commercial milestone. Alongside our participation in the Seoul Bio Hub program, ADLM provides a concrete opportunity to connect with diagnostics, animal health, and food safety stakeholders who share our conviction: that great diagnostics should not wait for patients to reach the laboratory. They should travel to the patient.
For partnership inquiries or to schedule a meeting at ADLM 2026, visit our Support page.
iGENETECH has been selected as one of the participating companies in the 2026 North America Market Entry Support Program, organized by Seoul Bio Hub under the Seoul Metropolitan Government. The program identifies Korean life sciences and medical technology companies with validated technology and global potential, and supports their structured entry into the North American market through mentorship, clinical network access, and U.S. ecosystem engagement.
What this program represents
North America remains the world's most demanding — and most consequential — market for in vitro diagnostics. Regulatory standards are high, clinical expectations are rigorous, and the bar for partnership is set accordingly. Being selected for this program is not simply an endorsement; it is the beginning of a structured process of market validation: engaging with U.S. healthcare experts, clinical stakeholders, and industry partners to test assumptions, refine our commercialization strategy, and build the relationships that matter.
For iGENETECH, this is a natural next step. The MoiM Dx Platform — a 16-plex molecular diagnostics system with results in under 60 minutes — was built for settings where diagnostic access is limited and speed is critical. That vision is as relevant in decentralized U.S. clinical environments as it is in resource-limited settings globally. The U.S. market does not simply represent scale. It represents validation at the highest standard.
What comes next
iGENETECH will be present at ADLM 2026 in Anaheim, California (July 26–30), our first major North America-facing commercial milestone. Alongside our participation in the Seoul Bio Hub program, ADLM provides a concrete opportunity to connect with diagnostics, animal health, and food safety stakeholders who share our conviction: that great diagnostics should not wait for patients to reach the laboratory. They should travel to the patient.
For partnership inquiries or to schedule a meeting at ADLM 2026, visit our Support page.